
Where We Are Now with LEN for PrEP



Gilead submits new drug application to U.S. Food and Drug Administration for twice-yearly lenacapavir for HIV prevention

Gilead submits marketing authorization application to the European Medicines Agency

European Medicines Agency agrees to accelerated review of LEN for PrEP

Gilead and Global Fund announce access agreement and finalize initial supply for nine

priority countries

EMA annnounces

recommendation of market authorization of LEN for PrEP. two months ahead of schedule

GILEAD PEPFAR recommits to partnership with Gilead in coordination with the Global Fund to deliver LEN for PrEP to at least 2 million people over 3 years

LEN injection and loading dose tablets are pre-qualified by WHO, the first products pre-qualified under WHO's new abridged PO procedure



PEPFAR, Global Fund and governments begin to procure initial LEN supplies; advocacy and additional investments needed to accelerate speed, scale, equity and impact

